BIC LEN HIV Treatment: New Single-Tablet Regime...

By João L. Carapinha

February 26, 2026

BIC/LEN HIV Treatment Maintains Suppression in Switch Studies Phase 3 results from Gilead Sciences' ARTISTRY-1 and ARTISTRY-2 trials, presented at the 2026 Conference on R...
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Ravulizumab aHUS Reimbursement Reassessment: Navigating New Evidence and Trea...
Global Drug Price Gaps Demand Better Drug Pricing Analysis
Aligning Market Access Strategies with the WHO’s Global Lung Health Resolution
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
South Africa NHI Bill Court Ruling Calls for Scrutiny
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Cholera Vaccination Campaign Amid Ongoing Outbreak
Promising Dual Immunotherapy for Anaplastic Thyroid Cancer
Advancing Newborn Screening for Sickle Cell Disease in Africa